Study shows evidence-based interventions can improve infant brain health
In the world of neurodevelopment, one thing is clear: the earlier the intervention the better. Infancy is a critical time in brain development, and neuroscientists are increasingly identifying factors that can negatively impact cognition and ones that can improve cognition early in life.
At the annual meeting of the Cognitive Neuroscience Society (CNS), researchers from the University of Minnesota are presenting new work on two early interventions: one on the potential use of engineered gut microbes for antibiotic-exposed infants and another on a choline supplement to treat infants exposed prenatally to alcohol.
Alzheimerâs Disease: Modifying Value Frameworks to Evaluate Current and Emerging Interventions
Value & Outcomes Spotlight Supplement Offers Diverse Perspectives From Leading Experts
Newswise Lawrenceville, NJ, USA March 15, 2021
Value & Outcomes Spotlight, a bimonthly ISPOR news publication for the global health economics and outcomes research (HEOR) community, announced today the publication of a special supplement exploring value assessment of new interventions in Alzheimer’s disease. The supplement, “Valuing Future Alzheimer’s Disease Treatments: The Need for a Holistic Approach,” was sponsored by Biogen and is based on a series of educational webinars produced by Biogen and ISPOR. The supplement to
Value & Outcomes Spotlight was published in March 2021.
Matthew Fullen, an assistant professor of counselor education in the School of Education, co-launched a research project to develop and evaluate an innovative training program. Suicide prevention among older adults represents the top goal of the phone-based training.
DAVID WAHLBERG
Using stem cells from monkeys with a condition like Parkinsonâs disease, UW-Madison researchers grew brain cells that produce a chemical depleted by the disease. When they injected the cells into the monkeysâ brains, the animalsâ Parkinsonâs-like rigid movements were replaced by more fluid walking and climbing. LOGAN WROGE, STATE JOURNAL
The results are promising enough that the researchers hope to begin work on applications for human patients soon, said UWâMadison neuroscientist Su-Chun Zhang, whose Waisman Center lab grew the brain cells.
âThis result in primates is extremely powerful, particularly for translating our discoveries to the clinic,â Zhang, senior author of the study published this month in the journal Nature Medicine, said in a statement.
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Monday, March 15, 2021 5:35PM IST (12:05PM GMT)
− Takeda will make manufacturing capacity available at IDT’s facilities in Germany
Takeda Pharmaceutical Company Limited
(TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be returned to Takeda to resume critical manufacturing for the planned launch of its dengue vaccine, subject to regulatory approvals.